SI2970132T1 - Inhibitorji argininmetiltransferaze in njihove uporabe - Google Patents

Inhibitorji argininmetiltransferaze in njihove uporabe

Info

Publication number
SI2970132T1
SI2970132T1 SI201431734T SI201431734T SI2970132T1 SI 2970132 T1 SI2970132 T1 SI 2970132T1 SI 201431734 T SI201431734 T SI 201431734T SI 201431734 T SI201431734 T SI 201431734T SI 2970132 T1 SI2970132 T1 SI 2970132T1
Authority
SI
Slovenia
Prior art keywords
methyltransferase inhibitors
arginine methyltransferase
arginine
inhibitors
methyltransferase
Prior art date
Application number
SI201431734T
Other languages
English (en)
Slovenian (sl)
Inventor
Richard Chesworth
Lorna Helen Mitchell
Gideon Shapiro
Keren Kalai Swinger
Original Assignee
Epizyme, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizyme, Inc. filed Critical Epizyme, Inc.
Publication of SI2970132T1 publication Critical patent/SI2970132T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI201431734T 2013-03-14 2014-03-14 Inhibitorji argininmetiltransferaze in njihove uporabe SI2970132T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361781051P 2013-03-14 2013-03-14
US201361876034P 2013-09-10 2013-09-10
EP14717371.0A EP2970132B1 (en) 2013-03-14 2014-03-14 Arginine methyltransferase inhibitors and uses thereof
PCT/US2014/029710 WO2014153226A1 (en) 2013-03-14 2014-03-14 Arginine methyltransferase inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
SI2970132T1 true SI2970132T1 (sl) 2021-02-26

Family

ID=50483598

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201431734T SI2970132T1 (sl) 2013-03-14 2014-03-14 Inhibitorji argininmetiltransferaze in njihove uporabe

Country Status (24)

Country Link
US (5) US9598374B2 (enExample)
EP (1) EP2970132B1 (enExample)
JP (1) JP6581076B2 (enExample)
KR (2) KR102028793B1 (enExample)
CN (2) CN109265400B (enExample)
AU (2) AU2014236146B2 (enExample)
BR (1) BR112015022785A2 (enExample)
CA (1) CA2903394C (enExample)
CY (1) CY1123637T1 (enExample)
DK (1) DK2970132T3 (enExample)
EA (1) EA030481B1 (enExample)
ES (1) ES2837034T3 (enExample)
HR (1) HRP20202008T1 (enExample)
HU (1) HUE052926T2 (enExample)
IL (2) IL241368B (enExample)
LT (1) LT2970132T (enExample)
MX (1) MX382991B (enExample)
PL (1) PL2970132T3 (enExample)
PT (1) PT2970132T (enExample)
RS (1) RS61231B1 (enExample)
SG (1) SG11201506972PA (enExample)
SI (1) SI2970132T1 (enExample)
WO (1) WO2014153226A1 (enExample)
ZA (1) ZA201507441B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9365555B2 (en) 2012-12-21 2016-06-14 Epizyme, Inc. PRMT5 inhibitors and uses thereof
WO2014100719A2 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
WO2014100695A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US9745291B2 (en) 2012-12-21 2017-08-29 Epizyme, Inc. PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof
CA2894157A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
EP3363434A1 (en) 2013-03-14 2018-08-22 Epizyme Inc Arginine methyltransferase inhibitors and uses thereof
EP2970137A1 (en) 2013-03-14 2016-01-20 Epizyme, Inc. Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof
US9447079B2 (en) 2013-03-14 2016-09-20 Epizyme, Inc. PRMT1 inhibitors and uses thereof
WO2014153208A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
EP2970136A1 (en) 2013-03-14 2016-01-20 Epizyme, Inc. Arginine methyl transferase inhibtors and uses thereof
US9120757B2 (en) 2013-03-14 2015-09-01 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US20160039767A1 (en) 2013-03-14 2016-02-11 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
LT2970132T (lt) * 2013-03-14 2021-01-11 Epizyme, Inc. Argininmetiltransferazės inhibitoriai ir jų panaudojimas
WO2014153235A2 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
EP2970135B1 (en) 2013-03-14 2018-07-18 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
EA201591532A1 (ru) 2013-03-15 2016-03-31 Эпизим, Инк. Ингибиторы carm1 и их применение
US9346802B2 (en) 2013-03-15 2016-05-24 Epizyme, Inc. CARM1 inhibitors and uses thereof
US9718816B2 (en) 2013-03-15 2017-08-01 Epizyme, Inc. 1-phenoxy-3-(alkylamino)-propan-2-ol derivatives as CARM1 inhibitors and uses thereof
WO2016022605A1 (en) 2014-08-04 2016-02-11 Epizyme, Inc. Prmt5 inhibitors and uses thereof
WO2016044576A1 (en) * 2014-09-17 2016-03-24 Epizyme, Inc. Salts, co-crystals, amorphous forms, and crystalline forms of an arginine methyltransferase inhibitor
CN110248676A (zh) * 2016-12-01 2019-09-17 葛兰素史密斯克莱知识产权发展有限公司 组合疗法
CA3045752A1 (en) * 2016-12-01 2018-06-07 Glaxosmithkline Intellectual Property Development Limited Methods of treating cancer
AU2017367300A1 (en) * 2016-12-01 2019-06-13 Glaxosmithkline Intellectual Property Development Limited Combination therapy
JP7305664B2 (ja) * 2018-03-01 2023-07-10 ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム タンパク質アルギニンメチルトランスフェラーゼの阻害剤としてのエタンジアミン－複素環誘導体
WO2019229613A1 (en) * 2018-05-31 2019-12-05 Glaxosmithkline Intellectual Property Development Limited Combined therapy with icos binding proteins and argininemethyltransferase inhibitors
CN113330009B (zh) * 2019-03-12 2024-02-09 四川科伦博泰生物医药股份有限公司 氮杂环化合物、其制备方法及用途
JP7609798B2 (ja) * 2019-03-25 2025-01-07 カリフォルニア インスティチュート オブ テクノロジー Ｐｒｍｔ５インヒビター及びその使用
WO2021023609A1 (en) * 2019-08-02 2021-02-11 Glaxosmithkline Intellectual Property Development Limited Combination of a type i protein arginine methyltransferase (type i prmt) inhibitor and a methionine adenosyltransferase ii alpha (mat2a) inhibitor
CN110950841A (zh) * 2019-11-22 2020-04-03 济南大学 一类新型三唑类化合物的合成及应用
KR102219251B1 (ko) 2020-03-03 2021-02-22 김명수 전문가 추천 플랫폼을 제공하는 서버 및 그 운용방법
CN111481532B (zh) * 2020-06-28 2020-09-22 南京中澳转化医学研究院有限公司 化合物28d在制备提高γ-珠蛋白表达量的药物中的应用

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH085859B2 (ja) 1986-07-01 1996-01-24 日本バイエルアグロケム株式会社 新規アルキレンジアミン類
US5204482A (en) 1988-07-28 1993-04-20 Hoffman-Laroche Inc. Compounds for treating and preventing cognitive diseases and depression and methods of making same
EP0352581A3 (de) 1988-07-28 1990-07-04 F. Hoffmann-La Roche Ag Aethylendiaminmonoamid-Derivate
US5932737A (en) 1994-12-02 1999-08-03 Fujisawa Pharmaceutical Co., Ltd. Peptide compounds for treatment of no-mediated diseases
SE9902765D0 (sv) 1999-07-21 1999-07-21 Astra Pharma Prod Novel compounds
CN1331326A (zh) * 2000-06-30 2002-01-16 上海博德基因开发有限公司 一种新的多肽——人精氨酸甲基转移酶(hrmt)32.12和编码这种多肽的多核苷酸
US20020090627A1 (en) 2000-10-05 2002-07-11 Rachel Meyers 27419, a novel human arginine-N-methyl transferase and uses thereof
DE10149370A1 (de) 2001-10-06 2003-04-10 Merck Patent Gmbh Pyrazolderivate
CN100445276C (zh) 2002-03-13 2008-12-24 詹森药业有限公司 用作组蛋白去乙酰酶抑制剂的磺酰基衍生物
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
EP1571146A4 (en) 2002-12-10 2010-09-01 Ono Pharmaceutical Co NITROGENIC HETEROCYCLIC COMPOUNDS AND THEIR MEDICAL USE
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
DE10315572A1 (de) 2003-04-05 2004-10-14 Merck Patent Gmbh Substituierte Pyrazole
GB0309637D0 (en) 2003-04-28 2003-06-04 Cancer Rec Tech Ltd Pyrazole compounds
WO2004098634A2 (en) 2003-04-30 2004-11-18 Government Of The United States Of America As Represented By The Sercretary Of The Department Of Health And Human Services National Institutes Of Health Protein arginine n-methyltransferase 2 (prmt-2)
US20050032794A1 (en) 2003-08-05 2005-02-10 Padia Janak K. Diamine derivatives of quinone and uses thereof
DE102004008807A1 (de) 2004-02-20 2005-09-08 Bayer Cropscience Ag Pyrazolopyrimidine
ES2705077T3 (es) 2004-03-15 2019-03-21 Janssen Pharmaceutica Nv Moduladores de receptores opioides
ATE492544T1 (de) 2004-08-26 2011-01-15 Pfizer Pyrazol-substituierte aminoheteroarylverbindungen als proteinkinasehemmer
DE602004023766D1 (de) 2004-08-31 2009-12-03 Univ North Carolina Dot1-histon-methyltransferasen als ziel zur identifizierung von therapeutika gegen leukämie
WO2006033995A2 (en) 2004-09-16 2006-03-30 Valeant Research And Development Thiazolidin-4-ones having anti-hepatitis b activity
US20080214654A1 (en) 2004-10-13 2008-09-04 Bayer Healthcare Ag Substituted Benzyloxy-Phenylmethylamide Derivatives
WO2006063356A1 (en) 2004-12-10 2006-06-15 Isis Phamaceuticals, Inc. Regulation of epigenetic control of gene expression
US20070060589A1 (en) 2004-12-21 2007-03-15 Purandare Ashok V Inhibitors of protein arginine methyl transferases
US20090036435A1 (en) 2005-01-21 2009-02-05 Astex Therapeutics Limited Pharmaceutical Compounds
US20060235037A1 (en) * 2005-04-15 2006-10-19 Purandare Ashok V Heterocyclic inhibitors of protein arginine methyl transferases
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
BRPI0614943A2 (pt) 2005-08-19 2011-04-26 Aventis Pharma Inc combinação de um agente hipnótico e composto de bisarila e heteroarila substituìdo e aplicação terapêutica da mesma
US8097708B2 (en) 2006-02-07 2012-01-17 Taisho Pharmaceutical Co., Ltd. 10a-Azalide compound
WO2007149782A2 (en) 2006-06-23 2007-12-27 University Of Medicine And Dentistry Of New Jersey Selective inhibitors for transferases
EP2035436B1 (en) 2006-06-26 2011-05-25 UCB Pharma S.A. Fused thiazole derivatives as kinase inhibitors
JP2009542809A (ja) * 2006-07-12 2009-12-03 メルク エンド カムパニー インコーポレーテッド グレリン受容体アンタゴニストとしての置換ピラゾール
JP2010503656A (ja) 2006-09-13 2010-02-04 アストラゼネカ アクチボラグ スピロ−オキサゾリジノン化合物と代謝共役型グルタミン酸受容体ポテンシエーターとしてのその使用
CL2007002670A1 (es) 2006-09-15 2008-05-16 Celgene Corp Soc Organizada Ba Compuestos derivados de n-metilaminometil-isoindolina; composicion farmaceutica; forma de dosificacion, util para tratar o prevenir enfermedades tales como cancer, dolor, trastorno pulmonar, trastorno del snc y aterosclerosis.
WO2008104077A1 (en) 2007-02-28 2008-09-04 Methylgene Inc. Small molecule inhibitors of protein arginine methyltransferases (prmts)
US20080312298A1 (en) 2007-04-11 2008-12-18 Kenneth William Foreman Methods for Identification of Modulators of Carm1 Methyl Transferase Activity
US20090062286A1 (en) 2007-05-04 2009-03-05 Kenneth William Foreman Crystal Structure of SMYD3 Protein
WO2009006577A2 (en) 2007-07-03 2009-01-08 The Regents Of The University Of Michigan Compositions and methods for inhibiting ezh2
US8133904B2 (en) 2007-09-07 2012-03-13 Jenrin Discovery, Inc. Cannabinoid receptor antagonists/inverse agonists useful for treating obesity
WO2009084695A1 (ja) 2007-12-28 2009-07-09 Carna Biosciences Inc. ２－アミノキナゾリン誘導体
JP2009179616A (ja) 2008-01-31 2009-08-13 Kowa Co ３−ナフチルピラゾール化合物
WO2009110985A2 (en) 2008-02-29 2009-09-11 Renovis, Inc. Amide compounds, compositions and uses thereof
WO2009126537A1 (en) 2008-04-07 2009-10-15 Syndax Pharmaceuticals, Inc. Administration of an inhibitor of hdac and an hmt inhibitor
JP5764822B2 (ja) 2008-08-27 2015-08-19 オンコセラピー・サイエンス株式会社 がんの治療および診断の標的遺伝子としてのｐｒｍｔ１
CN104211688B (zh) 2008-09-24 2016-04-13 巴斯夫欧洲公司 防治无脊椎动物害虫的吡唑化合物
US8323918B2 (en) 2008-12-12 2012-12-04 University Of South Carolina Chloroacetamidine based inhibitors and activity based probes for the protein arginine methytransferases
US20130345268A1 (en) 2009-02-13 2013-12-26 The Trustees Of Dartmouth College Methods and Compositions for the Treatment of RAS Associated Disorders
WO2010094009A2 (en) 2009-02-13 2010-08-19 Children's Hospital Medical Center Methods and compositions for the treatment of ras associated disorders
EP2221053A1 (de) 2009-02-20 2010-08-25 Albert-Ludwigs-Universität Freiburg Pharmazeutische Zusammensetzung enthaltend Hemmstoffe der Proteinmethyltransferase I und deren Verwendung zur Behandlung von Tumorerkrankungen
AU2010221818A1 (en) * 2009-03-11 2011-10-06 Auckland Uniservices Limited Prodrug forms of kinase inhibitors and their use in therapy
IN2012DN00352A (enExample) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
US20110021362A1 (en) 2009-07-20 2011-01-27 Constellation Pharmaceuticals Agents for stimulating activity of methyl modifying enzymes and methods of use thereof
WO2011079236A1 (en) 2009-12-22 2011-06-30 The Ohio State University Research Foundation Compositions and methods for cancer detection and treatment
WO2011082098A1 (en) 2009-12-30 2011-07-07 The Rockefeller University Lysine and arginine methyltransferase inhibitors for treating cancer
WO2011096210A1 (en) 2010-02-03 2011-08-11 Oncotherapy Science, Inc. Prmt1 and prmt6 for target genes of cancer therapy and diagnosis
WO2011096211A1 (en) 2010-02-03 2011-08-11 Oncotherapy Science, Inc. Whsc1 and whsc1l1 for target genes of cancer therapy and diagnosis
US20110251216A1 (en) 2010-02-19 2011-10-13 The Regents Of The University Of Michigan Compositions and methods for inhibiting ezh2
WO2012005805A1 (en) 2010-05-07 2012-01-12 Glaxosmithkline Llc Azaindazoles
ME02757B (me) 2010-05-07 2018-01-20 Glaxosmithkline Llc Indoli
US8895245B2 (en) 2010-09-10 2014-11-25 Epizyme, Inc. Inhibitors of human EZH2 and methods of use thereof
WO2012060760A1 (en) 2010-11-05 2012-05-10 Fujirebio Diagnostics Ab Molecular marker for cancer
WO2012068589A2 (en) 2010-11-19 2012-05-24 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
US8765792B2 (en) 2010-12-01 2014-07-01 Glaxosmithkline Llc Indoles
CN103391939B (zh) 2010-12-03 2016-03-09 Epizyme股份有限公司 作为表观遗传酶调节剂的经取代的嘌呤和7-氮杂嘌呤化合物
AU2011336272A1 (en) 2010-12-03 2013-06-20 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
AU2011341441A1 (en) 2010-12-03 2013-06-20 Epizyme, Inc. Modulators of histone methyltransferase, and methods of use thereof
WO2012075492A2 (en) 2010-12-03 2012-06-07 Epizyme, Inc. Carbocycle-substituted purine and 7-deazapurine compounds
AU2012223448B2 (en) 2011-02-28 2017-03-16 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
AU2013265266A1 (en) 2012-05-23 2015-01-15 Stemergie Biotechnology Sa Inhibitors of the activity of complex (III) of the mitochondrial electron transport chain and use thereof
AU2013310075A1 (en) 2012-08-30 2015-04-02 Nihon Nohyaku Co., Ltd. Endoparasite control agent and use thereof
IN2015MN00405A (enExample) 2012-08-30 2015-09-04 Univ Tokyo
US9745291B2 (en) 2012-12-21 2017-08-29 Epizyme, Inc. PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof
WO2014100719A2 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US20150344457A1 (en) 2012-12-21 2015-12-03 Epizyme, Inc. Methods of inhibiting prmt5
WO2014100695A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US9365555B2 (en) 2012-12-21 2016-06-14 Epizyme, Inc. PRMT5 inhibitors and uses thereof
CA2894157A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
EP3363434A1 (en) 2013-03-14 2018-08-22 Epizyme Inc Arginine methyltransferase inhibitors and uses thereof
US20160039767A1 (en) 2013-03-14 2016-02-11 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
US9120757B2 (en) 2013-03-14 2015-09-01 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
EP2970136A1 (en) 2013-03-14 2016-01-20 Epizyme, Inc. Arginine methyl transferase inhibtors and uses thereof
WO2014153208A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2014153235A2 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
EP2970137A1 (en) 2013-03-14 2016-01-20 Epizyme, Inc. Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof
LT2970132T (lt) * 2013-03-14 2021-01-11 Epizyme, Inc. Argininmetiltransferazės inhibitoriai ir jų panaudojimas
EP2970135B1 (en) 2013-03-14 2018-07-18 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
US9447079B2 (en) 2013-03-14 2016-09-20 Epizyme, Inc. PRMT1 inhibitors and uses thereof
US9718816B2 (en) 2013-03-15 2017-08-01 Epizyme, Inc. 1-phenoxy-3-(alkylamino)-propan-2-ol derivatives as CARM1 inhibitors and uses thereof
US9346802B2 (en) 2013-03-15 2016-05-24 Epizyme, Inc. CARM1 inhibitors and uses thereof
EA201591532A1 (ru) 2013-03-15 2016-03-31 Эпизим, Инк. Ингибиторы carm1 и их применение
US20170210751A1 (en) 2014-06-25 2017-07-27 Epizyme, Inc. Prmt5 inhibitors and uses thereof
EP3160477A4 (en) 2014-06-25 2018-07-04 Epizyme, Inc. Prmt5 inhibitors and uses thereof
WO2016022605A1 (en) 2014-08-04 2016-02-11 Epizyme, Inc. Prmt5 inhibitors and uses thereof
WO2016044576A1 (en) 2014-09-17 2016-03-24 Epizyme, Inc. Salts, co-crystals, amorphous forms, and crystalline forms of an arginine methyltransferase inhibitor
WO2016044585A1 (en) 2014-09-17 2016-03-24 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US20170283440A1 (en) 2014-09-17 2017-10-05 Epizyme, Inc. Carm1 inhibitors and uses thereof
EP3194398A4 (en) 2014-09-17 2018-02-21 Epizyme, Inc. Salts, co-crystals, amorphous forms, and crystalline forms of a co-activator-associated arginine methyltransferase 1 (carm1) inhibitor
US20170283400A1 (en) 2014-09-17 2017-10-05 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
EP3193608A4 (en) 2014-09-17 2018-05-02 Epizyme, Inc. Carm1 inhibitors and uses thereof
WO2016044641A2 (en) 2014-09-17 2016-03-24 Epizyme, Inc. Carm1 inhibitors and uses thereof
WO2016044626A1 (en) 2014-09-17 2016-03-24 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2017136699A1 (en) 2016-02-05 2017-08-10 Epizyme, Inc Arginine methyltransferase inhibitors and uses thereof
US20190083482A1 (en) 2017-09-18 2019-03-21 Epizyme, Inc. Prmt5 inhibitors and uses thereof

Also Published As

Publication number Publication date
IL241368B (en) 2019-07-31
US20170267642A1 (en) 2017-09-21
EP2970132A1 (en) 2016-01-20
AU2018203056B2 (en) 2020-05-21
CN109265400B (zh) 2022-10-04
US10081603B2 (en) 2018-09-25
AU2014236146A1 (en) 2015-09-10
SG11201506972PA (en) 2015-10-29
EA030481B1 (ru) 2018-08-31
US20190100496A1 (en) 2019-04-04
PL2970132T3 (pl) 2021-04-06
HRP20202008T1 (hr) 2021-02-19
US20210078951A1 (en) 2021-03-18
DK2970132T3 (da) 2020-12-21
WO2014153226A1 (en) 2014-09-25
EP2970132B1 (en) 2020-09-23
MX382991B (es) 2025-03-13
KR20190112334A (ko) 2019-10-04
KR20160003648A (ko) 2016-01-11
US20160024016A1 (en) 2016-01-28
AU2018203056A1 (en) 2018-07-19
CN105339351B (zh) 2018-11-06
JP2016516067A (ja) 2016-06-02
CY1123637T1 (el) 2022-03-24
ES2837034T3 (es) 2021-06-29
WO2014153226A9 (en) 2015-01-08
RS61231B1 (sr) 2021-01-29
MX2015012850A (es) 2016-06-24
HK1219736A1 (zh) 2017-04-13
IL241368A0 (en) 2015-11-30
CN105339351A (zh) 2016-02-17
KR102028793B1 (ko) 2019-10-07
CA2903394C (en) 2021-08-31
IL268189A (en) 2019-09-26
EA201591531A1 (ru) 2016-02-29
HUE052926T2 (hu) 2021-05-28
US11512053B2 (en) 2022-11-29
IL268189B (en) 2022-02-01
JP6581076B2 (ja) 2019-09-25
US20240182426A1 (en) 2024-06-06
ZA201507441B (en) 2021-01-27
CN109265400A (zh) 2019-01-25
BR112015022785A2 (pt) 2017-07-18
US9598374B2 (en) 2017-03-21
US10800743B2 (en) 2020-10-13
LT2970132T (lt) 2021-01-11
AU2014236146B2 (en) 2018-05-17
KR102158756B1 (ko) 2020-09-23
CA2903394A1 (en) 2014-09-25
PT2970132T (pt) 2020-12-30

Similar Documents

Publication Publication Date Title
IL268189B (en) Arginine methyltransferase inhibitors and their uses
IL267681A (en) Selective grp94 inhibitors and their uses
IL241370A0 (en) Carm1 inhibitors and their uses
IL240239A0 (en) erk inhibitors and their uses
GB2514443B (en) Electrosurgical methods and systems
EP2968339A4 (en) Mk2 inhibitors and uses thereof
ZA201505626B (en) Electrosurgical systems and methods
EP2994128A4 (en) ACC-HEMMER AND USES THEREOF
EP2994138A4 (en) ACC-HEMMER AND USES THEREOF
EP3200588A4 (en) Arginine methyltransferase inhibitors and uses thereof
EP2994139A4 (en) ACC-HEMMER AND USES THEREOF
HUE039504T2 (hu) Kináz inhibitor és alkalmazása
EP2943202A4 (en) IRAQ INHIBITORS AND USES THEREOF
ZA201508355B (en) Acc inhibitors and uses thereof
IL243728B (en) rorc2-inhibiting indole derivatives and their uses
IL244214A0 (en) Thienopiperidine derivative and its use
IL240553A0 (en) il-1ß inhibitory compounds and use thereof
GB201305813D0 (en) Compositions and methods
ZA201601880B (en) Hetero-transglycosylase and uses thereof
EP2968274A4 (en) MEROPENE DERIVATIVES AND USES THEREOF
GB201301393D0 (en) Kiddibidet and pottibidet
GB201306926D0 (en) Turbine and clip